Clinical expertise and experience in the life science or biotechnology environment is required. The Director of Americas Technical Support will develop and…From Illumina – Wed, 21 Jun 2017 18:12:40 GMT – View all San Diego, CA jobs
Work experience in the biotech, pharmaceutical or semiconductor industries is desirable. We are looking for driven, talented Senior Process Engineers to join…From Illumina – Wed, 21 Jun 2017 18:12:39 GMT – View all San Diego, CA jobs
Experience in Life Sciences, Biotech or Technology industries a plus. This position is a hands-on role focusing on analysis, evaluation, development,…From Illumina – Wed, 21 Jun 2017 18:12:37 GMT – View all San Diego, CA jobs
These individuals will provide technical leadership to new product introduction, production process development, improvement and sustaining efforts….From Illumina – Wed, 21 Jun 2017 18:12:35 GMT – View all San Diego, CA jobs
A minimum of two (2) years experience with business-to-business sales operations and onboarding processes (experience in biotech industry strongly preferred)….From Illumina – Wed, 21 Jun 2017 18:12:31 GMT – View all San Diego, CA jobs
Proven record of transferring new products to manufacturing and/or QC in a fast paced biotech environment. Proven data analysis and statistical interpretation…From Illumina – Wed, 21 Jun 2017 18:12:29 GMT – View all San Diego, CA jobs
PEAK Technical Staffing is Seeking: Lab Tech
Job duties include
1. Drying/firing substrates, blending paste, and taking thickness measurements.
2. Perform all activities in accordance with GMP/QSR requirements and established safety procedures.
inVentiv Health Consulting Releases Ninth Annual Survey of Biopharmaceutical Dealmakers, Projects Dealmaking Volume to Return to Historic Norms
SAN DIEGO, June 21, 2016 /PRNewswire/ — The ninth annual Dealmakers’ Intentions Study from inVentiv Health Consulting, an industry-leading consulting firm specializing in the biopharmaceutical industry, concludes that dealmaking will be robust in 2017, but is unlikely to reach the peak achieved in 2015.
The study, which was released during a Super Session at the BIO International Convention, provides a review of biopharmaceutical dealmakers’ intentions for the next twelve months. Results indicate that the year ahead will be a seller’s market, as buyers narrow their therapeutic focus and fiercely compete for entry and leadership in hot therapeutic areas or gain a technological advantage.
Download the full Dealmakers’ Intentions 2017 survey results.
“While dealmaking volume may continue to regress to the five-year average, decision makers are continuing to think creatively about new partnership opportunities,” said Neel Patel, Managing Director, inVentiv Health Consulting. “True innovators can expect to benefit from the emergence of new buyers and more financing options from the capital markets, permitting them to hold on to assets through commercialization in some disease areas. However, success with this strategy requires a clear understanding of the long-term potential of their assets in a rapidly evolving buyer’s market and payer landscape.”
Key findings include:
Innovators Can Retain Rights Longer, Thanks to New Buyers and Financing Options
- The trend away from large company dominance in total deal volume is continuing. Financing to small-cap and private biopharma companies saw significant continued growth in 2015 and remained steady through 2016 at $20 billion. Financing in this range – far above the $6-8 billion range that we saw from 2009 to 2012 – appears to be the new normal.
- Driving this trend is the emergence of new buyers and more financing options, from venture capital and other vehicles that are available to emerging companies and innovators.
Internal Factors Dominate Dealmaking, Some Unpredictable External Forces in Play
- The political environment and pricing pressures are expected to have less impact on dealmaking than anticipated. In fact, the major factors affecting dealmaking are internal, the biggest one being buyers’ ability to finance acquisitions, followed by the ability of buyers to access debt.
- However, the Trump administration’s stated intention to incentivize US companies to repatriate their overseas cash could spark a new wave of life science dealmaking.
Buyer’s Becoming More Risk Averse, Searching for More Precise Portfolio Additions
- Compared to 2016, the survey shows a greater mismatch between the assets buyers want to buy and those sellers want to sell. This suggests that buyers are becoming more risk averse and are waiting for later stage products with more data.
- However, pre-clinical assets are still generating higher overall interest relative to assets in phase I, II or II. These assets can be acquired much less expensively and are attractive as buyers narrow their therapeutic areas of focus and engage in stiff competition to break into hot therapeutic areas or gain technological advantage.
Imbalances in Supply and Demand Shape Seller’s and Buyer’s Markets
- Seller’s market exists in all areas of hepatic disease (including non-alcoholic steatohepatitis or NASH), women’s health and CNS-neurology assets.
- Innovation continues to drive demand in immuno-oncology and genetics. Hot areas and technologies of interest for licensing include CAR-T therapy, CRISPR-Cas9, cancer vaccines, biosimilars and antibody drug conjugates.
- A buyer’s market – most notably, preclinical assets – exists in cardiovascular, oncology, CNS-psychiatry, inflammation and autoimmune disease. The volume of development activity in oncology has kept this therapeutic area in a buyer’s market mode for a second year in a row.
Acceleration of Dealmaking Anticipated in 2019
- The discount rate gap between in-licensers and out-licensers is widening in 2017 (4% spread vs 2% in 2016), potentially indicating an acceleration in dealmaking activity over time. A similar trend occurred in 2013 and catalyzed the unprecedented dealmaking activity observed in 2015.
- Comparable growth in dealmaking activity can be anticipated in 2019, given the high discount rate gap. However, the activity is unlikely to reach the heights attained in 2015, as the discount rate spread is not as wide.
Deal Failures Driven by Factors Under Dealmakers’ Control
- The rate of discussions leading to a Confidential Disclosure Agreements (CDA) is expected to be much lower than in years past (27% in 2017 vs 65% in 2016), leading us to believe that companies are being more selective with whom they engage to begin the process.
- Buyers and sellers report similar pitfalls in the dealmaking environment. More than 75% of respondents zeroed in on two main reasons for deal failure: differing opinions about an asset’s commercial potential and unreasonable term expectations.
Connect with inVentiv Health Consulting
- Submit a request to have an inVentiv Health Consulting team member present survey results and implications for your business.
- Subscribe to our podcast for additional analysis of the survey results.
- Follow us on LinkedIn to read future blogs and insights on factors impacting deal-making.
About inVentiv Health Consulting
inVentiv Health Consulting is an industry-leading consulting firm specializing in the biopharmaceutical industry and is part of inVentiv Health, a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. We provide a comprehensive range of services across key areas including commercial strategy and planning, medical affairs, risk and program management and pricing and market access. Recognized by Forbes magazine as one of America’s Best Management Consulting Firms for two years running, our industry focus and depth of functional expertise, combined with strong scientific and market knowledge, uniquely position inVentiv Health Consulting to tackle highly complex business and market challenges to develop actionable client strategies. For more information, please visit inVentivHealth.com/Consulting.
inVentiv Health, Inc.
+1 202 210 5992
SOURCE inVentiv Health
The Lab Assistant I role is an entry-level support position within the Lab Services Division. Typical assignments are focused on general lab support tasks such as glass wash, autoclaving, media prep, instrumentation startup, inventor […
Creative Medical Technology Holdings Adds Immune Modulatory Cells for Stimulation of Perispinal Angiogenesis to Induce Regeneration of Degenerated Discs
Company Expands Intellectual Property Portfolio in Lower Back Pain Indication
PHOENIX and SAN DIEGO, June 21, 2017 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (the “Company”) (OTCQB:CELZ) announced the filing of intellectual property covering data supporting the use of immune system cells for stimulation of perispinal angiogenesis as a means of treating patients with lower back pain, as well as supporting intradiscal stem cell administration in patients suffering from degenerative disc disease.
The two patent applications, No. 62520773 and No. 62513670, filed on June 16th and June 1st, respectively, cover the novel use of cells, conventionally known as immune system cells, to stimulate formation of new blood vessels, a process termed angiogenesis. Several studies support the notion that patients suffering from lower back pain exhibit a reduction in blood flow to the lower back area. The Company has data supporting the use of immune cells from both the innate and adaptive arms of the immune system for stimulation of new blood vessel formation, which is believed to be beneficial for overcoming circulation defects in patients with lower back pain.
“I am extremely proud of the multidisciplinary approach that our development team is pursuing in covering any and all means of stimulating new blood vessel formation in order to overcome, what we perceive, to be a previously underappreciated mechanism of lower back pain pathology,” said Timothy Warbington, President and CEO of the Company. “It is important to note that as in the situation with our previously filed patents covering stimulating new blood vessel formation around the spine, we believe our approach is an ideal platform for companies and investigators performing intradiscal stem cell therapy.”
While numerous companies are currently injecting regenerative stem cells into the disc, the Company believes that due to intrinsic circulation abnormalities in the disc, these cells will not function optimally. The Company believes that initial correction of circulation defects in the area around the spine will increase efficacy of numerous existing cellular therapies.
“It is becoming more and more clear that immune system cells not only play a role in protection from disease but also possess various physiological functions,” said Thomas Ichim, Chief Scientific Officer of the Company. “The findings that we can leverage cells from both arms of the immune system, innate and adaptive, to triggering formation of new blood vessels, we hope will add to our increasing intellectual property portfolio covering ways of treating lower back pain using natural and cell based therapeutics.”
Creative Medical Technology Holdings, Inc. is a clinical-stage biotechnology company with three patented focus areas: 1) personalized stem cell procedures for sexual dysfunction and infertility; 2) universal, off-the-shelf amniotic fluid-based stem cells that possess superior healing potential without negative medical or ethical issues; and 3) treatment of disc degenerative disease using mesenchymal stem cells. Through our own research and collaborations with leading academic institutions, we have developed proprietary protocols, built an extensive intellectual property portfolio, developed complete treatment offerings for erectile dysfunction, and are performing ground-breaking research with our amniotic fluid-based stem cell.
For additional information visit www.CREATIVEMEDICALTECHNOLOGY.com.
This release may contain “forward-looking statements.” Forward-looking statements are identified by certain words or phrases such as “may”, “aim”, “will likely result”, “believe”, “expect”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “project”, “should”, “will pursue” and similar expressions or variations of such expressions. These forward-looking statements reflect the Company’s current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company’s most recent Forms 10-Q and 10-K and subsequent filings with the SEC for a further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward- looking statements in order to reflect events or circumstances after the date of this release.
SOURCE Creative Medical Technology Holdings, Inc.